New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 23, 2012
06:43 EDTVRNG, ESRXStocks with implied volatility below IV index mean; VRNG ESRX
Stocks with implied volatility movement; Vringo (VRNG), Express Scripts (ESRX) according to iVolatility.
News For VRNG;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
15:30 EDTESRXExpress Scripts options active after report of possible Humana sale
Express Scripts (ESRX) June 90 weekly and July weekly 83 puts are active on 14K puts (6K calls) after a report of possible Humana (HUM) sale. June and July put option implied volatility is at 23; compared to its 52-week range of 14 to 32. Active put volume suggests traders taking positions for downside price movement.
15:17 EDTESRXExpress Scripts falls in late afternoon
Subscribe for More Information
15:00 EDTESRXExpress Scripts falling, Anthem rising after report of possible Humana sale
Subscribe for More Information
09:16 EDTESRXBofA/Merrill healthcare tech analyst holds analyst/industry conference call
Analyst Willoughby discusses relevant themes across the Healthcare Distribution & Technology subsectors on an Analyst/Industry conference call to be held on June 1 at 11 am.
May 21, 2015
11:08 EDTESRXExpress Scripts management to meet with Jefferies
Meeting to be held in New York on May 26 hosted by Jefferies.
09:38 EDTESRXExpress Scripts starting to win some business, says Cleveland Research
Cleveland Research is hearing Express Scripts won the state of South Carolina business and renewal rates remain strong and on track to achieve guidance of 94%-97%.
May 20, 2015
11:51 EDTESRXExpress Scripts' Medco to pay $7.9M to resolve kickback allegations
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
10:00 EDTESRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
May 19, 2015
16:41 EDTESRXExpress Scripts initiated with a Neutral at Baird
Target $94.
11:50 EDTVRNGVringo says ZTE violated Brazilian court injunction
Vringoannounced that court-appointed experts in Brazil have issued a report stating that ZTE violated a Brazilian court injunction. Vringo received a preliminary injunction against ZTE on April 15, 2014, prohibiting ZTE from manufacturing, using, offering for sale, selling, installing, testing, or importing any 3G, 4G, or LTE infrastructure equipment in Brazil. The Federal and State Courts of Rio de Janeiro have, six times, denied ZTE's appeal of this injunction. Based on evidence of a potential violation of the injunction, the State Court of Rio de Janeiro appointed experts to investigate ZTE's activities in Brazil. Vringo now plans to file a motion for contempt with the Court requesting that punitive measures be taken against ZTE for its violation of the injunction.
May 18, 2015
09:12 EDTVRNGVringo announces favorable ruling by Brazilian court
Vringo announced that the Brazilian Federal Court in Rio de Janeiro has denied ZTE's motion for a preliminary injunction against Vringo Infrastructure. Vringo received a preliminary injunction against ZTE on April 15, 2014. Since that time, ZTE has sought to overturn the injunction by filing numerous appeals. ZTE's most recent attempt to overturn the injunction was a lawsuit filed by ZTE's Brazilian subsidiary. In that lawsuit, ZTE requested a preliminary injunction against Vringo, seeking the Brazilian court impose a royalty rate for a temporary license between the parties. The Court denied ZTE's request for preliminary injunction based solely on the evidence presented in ZTE's own filing. Among other points, the Court found that there was no evidence that ZTE was willing to effectively negotiate a license prior to Vringo's filing an infringement lawsuit against ZTE in the Rio de Janeiro State Court. Following this ruling, the preliminary injunction against ZTE remains in place.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use